Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $6.98M
• Dividend Yield: N/A
• Average Volume (3M): 92.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 3,814,853
• 10 Day Avg. Volume: 67,881
• 30 Day Avg. Volume: 92,339
• PEG Ratio: -12.69
• Price to Book (P/B): 285.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -260.61
• Enterprise Value/Market Cap: 670.59
• Enterprise Value/Revenue: 1.51K
• Enterprise Value/Gross Profit: 8.14K
• Enterprise Value/Ebitda: -62.34
• 1Y Price Target: $14.00
• Price Target Upside: 665.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $2.00 ▲(9.29%Upside)

Mainz Biomed B.V.'s overall stock score is primarily impacted by financial instability and poor technical indicators. The company's significant financial challenges and weak market momentum are key concerns, while valuation metrics provide little incentive for investment.

Positive Factors

Market Opportunity

Mainz Biomed has the potential to capture a share of the $4B colorectal cancer screening market with its at-home, fecal-based testing kits, similar to the successful Cologuard test.

Strategic Partnerships

An agreement with Quest Diagnostics for the ReconAAsense study, with an option for commercialization, enhances Mainz Biomed's strategic partnerships.

Technological Advancements

The company's Next Generation Test uses mRNA biomarkers to enhance the detection of pre-cancerous advanced adenomas, potentially preventing colorectal cancer.

Negative Factors

Clinical Study Challenges

The feasibility study aims to evaluate the panel and machine learning algorithm in a clinical sample set, but the outcome of sensitivity, specificity, and consistency tests is still pending.

Competition

Existing tests with a similar format, such as Cologuard, have already achieved commercial success with over $2B in annual sales, creating competition for Mainz Biomed.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, clinics, and laboratories. The company's primary revenue stream is derived from the commercialization of its flagship colorectal cancer screening test. Additionally, Mainz Biomed engages in strategic partnerships and collaborations with research institutions and healthcare organizations to enhance and expand its diagnostic offerings. These partnerships may contribute to revenue through joint development agreements, licensing deals, and the sharing of research findings that support product innovation and market expansion.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. faces significant financial challenges, notably negative profitability and high leverage. While there are improvements in equity and free cash flows, the company's profitability remains pressured by negative margins and reliance on external funding.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
893.99K	895.48K	529.88K	577.35K	493.56K
	Gross Profit
574.88K	509.66K	182.15K	177.62K	123.08K
	EBIT
-18.70M	-26.64M	-26.17M	-9.38M	-325.81K
	EBITDA
-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
	Net Income Common Stockholders
-21.65M	-26.30M	-26.45M	-12.07M	-886.18K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.24M	7.07M	17.14M	8.73M	122.57K
	Total Assets
13.24M	15.41M	20.24M	10.04M	673.27K
	Total Debt
3.27M	7.42M	3.23M	2.58M	2.98M
	Net Debt
-2.96M	349.86K	-13.91M	-6.15M	2.86M
	Total Liabilities
7.19M	12.16M	6.14M	3.68M	3.41M
	Stockholders Equity
6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow		Free Cash Flow
-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
	Operating Cash Flow
-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
	Investing Cash Flow
-198.82K	-1.90M	-658.48K	1.20M	-9.69K
	Financing Cash Flow
16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 1.83 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.64, and below the 200-day MA of 6.51, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 31.06 is Neutral, neither overbought nor oversold. The STOCH value of 26.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	65 Neutral	$16.41M	―	-25.29%	―	26.67%	44.02%
INBS	63 Neutral	$13.20M	―	-126.34%	―	3.87%	91.76%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
BNGO	45 Neutral	$12.28M	―	-127.82%	―	-24.04%	84.11%
BIAF	42 Neutral	$7.84M	―	-290.85%	―	78.40%	22.41%
MYNZ	41 Neutral	$6.98M	―	-809.29%	―	―	―
TRIB	35 Underperform	$11.80M	―	77.20%	―	-3.76%	39.52%